{"id":"bg00012-dmf-tecfidera","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Flushing"},{"rate":"30-40","effect":"Gastrointestinal distress (nausea, diarrhea, abdominal pain)"},{"rate":"5-10","effect":"Lymphopenia"},{"rate":"3-5","effect":"Elevated liver enzymes"},{"rate":"10-15","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL555694","moleculeType":"Small molecule","molecularWeight":"661.66"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dimethyl fumarate is a fumaric acid ester that crosses the blood-brain barrier and activates Nrf2, a transcription factor that upregulates antioxidant and cytoprotective genes. This reduces neuroinflammation and oxidative stress in multiple sclerosis lesions. Additionally, DMF modulates immune cell populations, reducing pro-inflammatory T cells and promoting regulatory immune responses.","oneSentence":"BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and modulate immune responses in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:05.010Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis (RRMS)"},{"name":"Secondary progressive multiple sclerosis (SPMS) with relapses"}]},"trialDetails":[{"nctId":"NCT03331835","phase":"PHASE4","title":"A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-11-03","conditions":"Psoriasis Vulgaris","enrollment":210},{"nctId":"NCT05269888","phase":"","title":"Covid-19 Vaccine Immune Response in Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospitals of North Midlands NHS Trust","startDate":"2022-02-16","conditions":"Multiple Sclerosis","enrollment":240},{"nctId":"NCT04792567","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-04-19","conditions":"Secondary Progressive Multiple Sclerosis","enrollment":41},{"nctId":"NCT04468165","phase":"","title":"Effectiveness and Safety of Generic Delayed-Release Dimethyl Fumarate (Sclera® or Marovarex ®, Hikma) in Routine Medical Practice in the Treatment of Relapsing-Remitting Multiple Sclerosis in MENA Region","status":"COMPLETED","sponsor":"Hikma Pharmaceuticals LLC","startDate":"2021-02-23","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":160},{"nctId":"NCT05779449","phase":"NA","title":"Targeting the Gut Dysbiosis to Treat Inflammation-driven Synaptopathy in MS","status":"RECRUITING","sponsor":"Neuromed IRCCS","startDate":"2023-07-26","conditions":"Patient Participation","enrollment":100},{"nctId":"NCT04221191","phase":"","title":"Dimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEP","status":"COMPLETED","sponsor":"Biogen","startDate":"2019-08-19","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":353},{"nctId":"NCT04570670","phase":"PHASE1","title":"Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects","status":"COMPLETED","sponsor":"Banner Life Sciences LLC","startDate":"2017-01-06","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":50},{"nctId":"NCT04263610","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-09-04","conditions":"Plaque Psoriasis","enrollment":190},{"nctId":"NCT02739542","phase":"PHASE4","title":"Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2016-03-19","conditions":"Multiple Sclerosis (MS)","enrollment":87},{"nctId":"NCT04925778","phase":"","title":"Observational Study in Patients With Relapsing-Remitting Multiple Sclerosis Switched to Bafiertam® From Dimethyl Fumarate","status":"WITHDRAWN","sponsor":"Banner Life Sciences LLC","startDate":"2021-06-30","conditions":"Relapsing Remitting Multiple Sclerosis","enrollment":""},{"nctId":"NCT02471560","phase":"PHASE4","title":"Tecfidera and the Gut Microbiota","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-11-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":36},{"nctId":"NCT02907177","phase":"PHASE3","title":"Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)","status":"TERMINATED","sponsor":"Actelion","startDate":"2017-03-30","conditions":"Multiple Sclerosis","enrollment":136},{"nctId":"NCT02410278","phase":"PHASE4","title":"Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-03-12","conditions":"Multiple Sclerosis","enrollment":102},{"nctId":"NCT04022473","phase":"PHASE1","title":"Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers","status":"COMPLETED","sponsor":"Banner Life Sciences LLC","startDate":"2019-07-07","conditions":"Multiple Sclerosis","enrollment":210},{"nctId":"NCT02201849","phase":"PHASE1","title":"A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-07","conditions":"Multiple Sclerosis","enrollment":104},{"nctId":"NCT03255382","phase":"PHASE3","title":"A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-08-22","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT02461069","phase":"PHASE4","title":"Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2015-05-06","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":67},{"nctId":"NCT03092544","phase":"PHASE4","title":"Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients","status":"UNKNOWN","sponsor":"Multiple Sclerosis Center of Northeastern New York","startDate":"2015-02","conditions":"Multiple Sclerosis","enrollment":57},{"nctId":"NCT02823951","phase":"","title":"Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®","status":"COMPLETED","sponsor":"IMS HEALTH GmbH & Co. OHG","startDate":"2016-02","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":479},{"nctId":"NCT02474082","phase":"PHASE3","title":"Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-04","conditions":"Psoriasis","enrollment":202},{"nctId":"NCT02097849","phase":"PHASE2","title":"Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-02-28","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":71},{"nctId":"NCT02438137","phase":"PHASE2","title":"Dimethyl Fumarate for Obstructive Sleep Apnea","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2015-05","conditions":"Obstructive Sleep Apnea, OSA, Sleep Apnea","enrollment":65},{"nctId":"NCT02343159","phase":"PHASE4","title":"Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.","status":"TERMINATED","sponsor":"Biogen","startDate":"2015-02-28","conditions":"Multiple Sclerosis","enrollment":84},{"nctId":"NCT02428231","phase":"PHASE3","title":"Tecfidera Slow-Titration Study","status":"TERMINATED","sponsor":"Biogen","startDate":"2015-04","conditions":"Multiple Sclerosis","enrollment":62},{"nctId":"NCT02776072","phase":"","title":"Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"Biogen","startDate":"2016-05","conditions":"Multiple Sclerosis","enrollment":2978},{"nctId":"NCT02683863","phase":"PHASE4","title":"Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers","status":"COMPLETED","sponsor":"Multiple Sclerosis Center of Northeastern New York","startDate":"2015-08","conditions":"Multiple Sclerosis","enrollment":20},{"nctId":"NCT02117050","phase":"PHASE4","title":"RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2014-06","conditions":"Multiple Sclerosis","enrollment":1},{"nctId":"NCT02090413","phase":"PHASE4","title":"Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-05","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":241},{"nctId":"NCT02955693","phase":"PHASE1","title":"Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2016-09","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT02519413","phase":"","title":"Tecfidera Lymphocyte Chart Review","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-07","conditions":"Multiple Sclerosis","enrollment":483},{"nctId":"NCT01815723","phase":"PHASE3","title":"Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis","status":"WITHDRAWN","sponsor":"Forward-Pharma GmbH","startDate":"2016-06","conditions":"Plaque Psoriasis","enrollment":""},{"nctId":"NCT02159573","phase":"","title":"Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":530},{"nctId":"NCT02090348","phase":"PHASE4","title":"Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate","status":"WITHDRAWN","sponsor":"Biogen","startDate":"2015-06","conditions":"Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis","enrollment":""},{"nctId":"NCT00420212","phase":"PHASE3","title":"Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-01","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1234},{"nctId":"NCT00451451","phase":"PHASE3","title":"Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Biogen","startDate":"2007-06","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":1417},{"nctId":"NCT02171208","phase":"PHASE1","title":"A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-06","conditions":"Healthy","enrollment":80},{"nctId":"NCT01915901","phase":"PHASE1","title":"PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily","status":"COMPLETED","sponsor":"Biogen","startDate":"2013-08","conditions":"Healthy","enrollment":175},{"nctId":"NCT01352988","phase":"PHASE2","title":"Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus","status":"COMPLETED","sponsor":"University Hospital Muenster","startDate":"2011-07","conditions":"Lupus Erythematosus, Cutaneous","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"BG00012 (DMF) (Tecfidera®.)","genericName":"BG00012 (DMF) (Tecfidera®.)","companyName":"Multiple Sclerosis Center of Northeastern New York","companyId":"multiple-sclerosis-center-of-northeastern-new-york","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BG00012 (dimethyl fumarate) activates the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway to reduce oxidative stress and modulate immune responses in the central nervous system. Used for Relapsing-remitting multiple sclerosis (RRMS), Secondary progressive multiple sclerosis (SPMS) with relapses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}